Companies jointly work on cervical cancer drug
March 08 2005 1:00 AM ET
Minnesota-based 3M and Japanese firm Takeda Pharmaceuticals are jointly developing a drug to treat cervical dysplasia--the precursor to cervical cancer, The Wall Street Journal reports. Cervical dysplasia--abnormal cell growth in the cervix that is considered precancerous--is believed to be linked in almost all cases to certain strains of the human papillomavirus. The experimental drug aims to stimulate the body's immune system to destroy HPV-infected cells in the cervix. The still-unnamed drug is currently in Phase I clinical trials. Phase II tests are expected to begin later this year. Cervical cancer is an AIDS-defining condition in HIV-positive women.
- #TBT: They Died in the Closet
- Omar Sharif Jr. Featured on Arabic TV News
- The Top 175 Essential Films of All Time for LGBT Viewers
- Leslie Jordan Banishes Antigay Starbucks Patrons: 'Get Out of My House!'
- Op-ed: The Far-Reaching Consequences of Dating App Racism
- Living Trans, From Iran to New York City